(NASDAQ:ARTL) SOLANA BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced the pricing of its previously announced underwritten public offering of 640,924 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 40,894 shares of Artelo’s common stock at a price to the public of $4.399 per pre-funded warrant, which represents the per share public offering price of each share of Artelo’s common stock less the $0.001 per share exercise price for each pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $3.0 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purch
Related Questions
How will the issuance of 640,924 new shares and the accompanying pre‑funded warrants dilute existing shareholders and affect ARTL's earnings per share?
What are the intended uses of the approximately $3 million net proceeds and how will they support Artelo Biosciences’ near‑term clinical and commercial milestones?
How does the $4.40 per share pricing, including the warrant terms and underwriting discounts, compare to ARTL’s recent trading range and to similar financing deals in the biotech sector?